TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39625230

Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg every 4 weeks (Q4W) with topical corticosteroids (TCS)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg every 2 weeks (Q2W) with topical corticosteroids (TCS)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study: 39625244

Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg daily starting post-operative day 2 until 1 day after chest tube removal
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control cohort (previously published, n = 25)
Number of subjects: 9
Study: 39625263

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) + Treatment as usual (TAU)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 144
Study: 39625429

Group type: EXPERIMENTAL
Intervention: Exome+ assay (whole exome sequencing plus ∼300,000 single nucleotide polymorphisms)
Number of subjects: 98222

Group type: EXPERIMENTAL
Intervention: Communication of positive results by genetic counselors
Number of subjects: 98222

Group type: EXPERIMENTAL
Intervention: Access to Exome+ assays for research
Number of subjects: 98222
Study: 39625478

Group type: EXPERIMENTAL
Intervention: Duvelisib (25 mg orally twice daily) with docetaxel (75 mg/m2 IV every 21-days)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Duvelisib with docetaxel
Number of subjects: 26
Study: 39625569

Group type: EXPERIMENTAL
Intervention: Pexidartinib with neoadjuvant paclitaxel
Number of subjects: 9

Group type: COMPARATOR
Intervention: Standard neoadjuvant therapy with paclitaxel and adriamycin/cyclophosphamide
Number of subjects: 9
Study: 39625640

Group type: EXPERIMENTAL
Intervention: Hand massage (10 minutes total, applied before each brachytherapy session for 1 week)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study: 39625696

Group type: EXPERIMENTAL
Intervention: Single intravenous 15 mg/kg amikacin dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flat 1500-mg dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flat 3500-mg dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: 15 mg/kg dosing
Number of subjects: 0
Study: 39625722

Group type: EXPERIMENTAL
Intervention: Fostamatinib, 150 mg orally twice daily for 14 days
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Fostamatinib
Number of subjects: 400
Study: 39625741

Group type: EXPERIMENTAL
Intervention: Dyadic eHealth intervention
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 280
Study: 39626074

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Estradiol transdermal patches
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo for sertraline
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo for estradiol
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 62
Study: 39626127

Group type: EXPERIMENTAL
Intervention: IV ocrelizumab 600 mg every 24 weeks
Number of subjects: 678
Study: 39626160

Group type: EXPERIMENTAL
Intervention: Niraparib 300 mg orally once daily on a 28-day cycle
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 37
Study: 39626227

Group type: EXPERIMENTAL
Intervention: Advanced Symptom Management System (ASyMS)
Number of subjects: 29
Study: 39626287

Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 49

Group type: COMPARATOR
Intervention: Ibrutinib
Number of subjects: 49
Study: 39626300

Group type: EXPERIMENTAL
Intervention: Inaticabtagene Autoleucel (Inati-cel) infusion
Number of subjects: 48
Study: 39626332

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT with CF)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Supportive Psychotherapy (SP)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: ACT with CF
Number of subjects: 124

Group type: COMPARATOR
Intervention: SP
Number of subjects: 124
Study: 39626345

Group type: EXPERIMENTAL
Intervention: Adipocyte size measurement in various fat depots (subcutaneous, visceral, retroperitoneal, mammary)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Adipocyte size measurement in mammary fat at autopsy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Correlation of adipocyte size with BMI at death
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Assessment of tumor infiltration in visceral fat
Number of subjects: 22
Study: 39626378

Group type: EXPERIMENTAL
Intervention: Aβ-hTreg (VT301) low dose
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Aβ-hTreg (VT301) high dose
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 6
Study: 39626407

Group type: EXPERIMENTAL
Intervention: Broad test battery including Short Physical Performance Battery, Single Leg Stance, Chair Stand Test, 10mWT, 2 Minute Walk Tests, limb circumference, dynamometry, Clinical Frailty Scale, SHARE-Frailty Instrument, Numerical Pain Rating Scale, Short Form-12
Number of subjects: 74
Study: 39626445

Group type: EXPERIMENTAL
Intervention: Reirradiation of diffuse midline glioma patients
Number of subjects: 0
Study: 39626671

Group type: EXPERIMENTAL
Intervention: Neural stem cell transplantation (NSI-566)
Number of subjects: 4
Study: 39626674

Group type: EXPERIMENTAL
Intervention: HIV infection
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Clonal hematopoiesis (CH)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Control group (without HIV)
Number of subjects: 345
Study: 39627012

Group type: EXPERIMENTAL
Intervention: Hazelnut flour added to gluten-free corn flour in different amounts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (gluten-free corn flour without hazelnut flour)
Number of subjects: 0
Study: 39627123

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) interventions selected by an algorithm
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Conventional pain disability measures (Pain Disability Index and adapted Quebec Back Pain Disability Scale)
Number of subjects: 12
Study: 39627133

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitor (ICI) rechallenge
Number of subjects: 1016
Study: 39627139

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus platinum and gemcitabine (PG)
Number of subjects: 26
Study: 39627217

Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg daily for 12 months
Number of subjects: 35
Study: 39627222

Group type: EXPERIMENTAL
Intervention: Benznidazole regimens and combinations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MultiCruzi serological method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCR data
Number of subjects: 0
Study: 39627496

Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training (PCST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adapted Pain Coping Skills Training (PCST)
Number of subjects: 0
Study: 39627624

Group type: EXPERIMENTAL
Intervention: Submucosal dexamethasone (8 mg, 2 mL)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Submucosal normal saline
Number of subjects: 25
Study: 39627701

Group type: EXPERIMENTAL
Intervention: RSM01 (300 mg IV, 300 mg IM, 1000 mg IV, 3000 mg IV, 600 mg IM)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 39627771

Group type: EXPERIMENTAL
Intervention: Healthy food nudges (combination of placement and property nudges)
Number of subjects: 638

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 638
Study: 39627785

Group type: EXPERIMENTAL
Intervention: Return-to-work expectancy
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Health literacy
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Pain severity
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Self-perceived health
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Sleep quality
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Work satisfaction
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Disability
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Long-lasting disorder expectation
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Healthcare utilization and productivity loss
Number of subjects: 509
Study: 39627786

Group type: EXPERIMENTAL
Intervention: Melatonin treatment for 2 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 39627789

Group type: EXPERIMENTAL
Intervention: Adapted STAIR-NT intervention (massed treatment model with four 60-min sessions of skill building and two weeks of four 60-min sessions of narrative therapy)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 80
Study: 39627794

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (n=112)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Standard care (n=107)
Number of subjects: 219
Study: 39627831

Group type: EXPERIMENTAL
Intervention: Active pulse electromagnetic field therapy and standard exercise training
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham pulse electromagnetic field therapy and standard exercise training
Number of subjects: 48
Study: 39627888

Group type: EXPERIMENTAL
Intervention: Bactogram method applied to suction blister wounds
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bactogram method with chromogenic agar
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Quantification methods based on visual scoring and image analysis
Number of subjects: 24
Study: 39628466

Group type: EXPERIMENTAL
Intervention: Polyphenol-rich supplement (specific dosage and duration not mentioned)
Number of subjects: 0
Study: 39628618

Group type: EXPERIMENTAL
Intervention: Miglustat (100 mg twice daily to 200 mg three times daily)
Number of subjects: 17
Study: 39628893

Group type: EXPERIMENTAL
Intervention: Endoscopic surgery (ES) for hematoma evacuation within 24 hours after bleeding onset.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Endoscopic surgery (ES) for hematoma evacuation.
Number of subjects: 10
Study: 39629185

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) and positive psychology therapy (PPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39629586

Group type: EXPERIMENTAL
Intervention: Aortic Valve Replacement (AVR)
Number of subjects: 39
Study: 39629675

Group type: EXPERIMENTAL
Intervention: Dynamic assessment using the Glaspey Dynamic Assessment of Phonology's scoring system
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Modified cycles approach administered by an SLT and a student clinician
Number of subjects: 2
Study: 39629836

Group type: EXPERIMENTAL
Intervention: CAM2038 subcutaneous (SC) buprenorphine (BPN) extended-release injections
Number of subjects: 428

Group type: COMPARATOR
Intervention: Daily sublingual (SL) BPN/naloxone (BPN/NX) tablets
Number of subjects: 428
Study: 39629943

Group type: EXPERIMENTAL
Intervention: Phone-delivered, motivational interviewing-based parental support program (counseling every other week for 1 year)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Phone-delivered, motivational interviewing-based parental support program
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard advice on toothbrushing and sugar reduction (control group)
Number of subjects: 151
Study: 39630028

Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA) treatment
Number of subjects: 4174

Group type: COMPARATOR
Intervention: Non-OCA treatment (control)
Number of subjects: 4174
Study: 39630057

Group type: EXPERIMENTAL
Intervention: Modakafusp alfa at 1.5 mg/kg every 4 weeks (Q4W)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Modakafusp alfa therapy
Number of subjects: 106
Study: 39630067

Group type: EXPERIMENTAL
Intervention: Beta-lactam antibiotics (11 different types)
Number of subjects: 57
Study: 39630083

Group type: EXPERIMENTAL
Intervention: Olanzapine and Samidorphan
Number of subjects: 0
Study: 39630397

Group type: EXPERIMENTAL
Intervention: Furosemide administration
Number of subjects: 27
Study: 39630545

Group type: EXPERIMENTAL
Intervention: Pediatric Quality of Life Inventory (PedsQL) scale
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Functional Status Scale (FSS)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Post-traumatic stress syndrome (PTSS) assessment
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Trajectory groups identification
Number of subjects: 135
Study: 39630588

Group type: EXPERIMENTAL
Intervention: Novel foot (Ottobock Evanto)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Everyday foot
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparator foot (Össur Pro-Flex XC)
Number of subjects: 20
Study: 39630633

Group type: EXPERIMENTAL
Intervention: HCS intervention communities
Number of subjects: 67

Group type: COMPARATOR
Intervention: Wait-list control communities
Number of subjects: 67
Study: 39630656

Group type: EXPERIMENTAL
Intervention: ICAN Discussion Aid
Number of subjects: 1733

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1733
Study: 39630680

Group type: EXPERIMENTAL
Intervention: CAB (clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 173
Study: 39630726

Group type: EXPERIMENTAL
Intervention: Breathing exercises (diaphragmatic and pursed lip breathing), practiced once a day, 3 days a week for 4 weeks.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 54
Study: 39630812

Group type: EXPERIMENTAL
Intervention: Group singing
Number of subjects: 210

Group type: COMPARATOR
Intervention: Audiobook club (control)
Number of subjects: 210
Study: 39630823

Group type: EXPERIMENTAL
Intervention: CIM2 intervention
Number of subjects: 350

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 350
Study: 39630935

Group type: EXPERIMENTAL
Intervention: ABC + 3TC + AZT
Number of subjects: 13

Group type: COMPARATOR
Intervention: ABC
Number of subjects: 13

Group type: COMPARATOR
Intervention: 3TC
Number of subjects: 13
Study: 39631042

Group type: EXPERIMENTAL
Intervention: Budesonide oral suspension (BOS) 2.0 mg twice daily
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study: 39631193

Group type: EXPERIMENTAL
Intervention: ICU survivors
Number of subjects: 642

Group type: COMPARATOR
Intervention: Non-survivors
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: ICU patients
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Surviving patients
Number of subjects: 642

Group type: COMPARATOR
Intervention: Relatives of surviving patients
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 642
Study: 39631208

Group type: COMPARATOR
Intervention: A-HCLF diet (higher-carbohydrate lower-fat diet with refined carbohydrate sources)
Number of subjects: 193

Group type: COMPARATOR
Intervention: C-HCLF diet (higher-carbohydrate lower-fat diet with minimally refined carbohydrate sources)
Number of subjects: 193

Group type: COMPARATOR
Intervention: LCHF diet (low-carbohydrate high-fat diet)
Number of subjects: 193

Group type: COMPARATOR
Intervention: LCHF diet
Number of subjects: 193
Study: 39631531

Group type: EXPERIMENTAL
Intervention: Cardiology care
Number of subjects: 52011

Group type: COMPARATOR
Intervention: Primary care
Number of subjects: 52011

Group type: COMPARATOR
Intervention: Other specialties (internist/neurologist/geriatrician)
Number of subjects: 52011
Study: 39631536

Group type: EXPERIMENTAL
Intervention: ICECaP intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 39631702

Group type: EXPERIMENTAL
Intervention: D-Cycloserine (100 mg) with daily intermittent theta-burst stimulation (iTBS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo with daily intermittent theta-burst stimulation (iTBS)
Number of subjects: 50
Study: 39631846

Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab (D+T)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 161
Study: 39632005

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1905

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1905

Group type: EXPERIMENTAL
Intervention: Postdischarge major bleeding
Number of subjects: 1905

Group type: EXPERIMENTAL
Intervention: Major bleeding (MB) after both procedures
Number of subjects: 1905
Study: 39632107

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with cadonilimab (SOX regimen with cadonilimab)
Number of subjects: 37
Study: 39632119

Group type: EXPERIMENTAL
Intervention: T2D genetic risk estimates and lifestyle advice
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: T2D genetic risk estimates, lifestyle advice, and Fitbit's step goal setting and prompt functions
Number of subjects: 355

Group type: COMPARATOR
Intervention: Control group (Fitbit device only)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Both intervention groups
Number of subjects: 355
Study: 39632125

Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound (HIFU)
Number of subjects: 3328

Group type: COMPARATOR
Intervention: Radical prostatectomy (RP)
Number of subjects: 3328
Study: 39632341

Group type: EXPERIMENTAL
Intervention: LEM 5 mg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: LEM 10 mg
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 39632499

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Higher MVPA
Number of subjects: 140
Study: 39632722

Group type: EXPERIMENTAL
Intervention: Matching algorithm using imaging and clinical variables
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual screening by clinicians
Number of subjects: 0
Study: 39633037

Group type: EXPERIMENTAL
Intervention: Moderate-to-severe asthma (CASI ≥ 4)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Mild asthma (CASI < 4)
Number of subjects: 425

Group type: COMPARATOR
Intervention: No asthma
Number of subjects: 425
Study: 39633105

Group type: EXPERIMENTAL
Intervention: Automated text messaging program prompting weekly BP checks for 6 months.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Automated text messaging program.
Number of subjects: 300
Study: 39633112

Group type: EXPERIMENTAL
Intervention: Melatonin 60 mg/day starting 5 days before surgery
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo treatment starting 5 days before surgery
Number of subjects: 34
Study: 39633142

Group type: EXPERIMENTAL
Intervention: Real-time 2D intraoperative ultrasound (iUS) bone registration
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Initial registration using iUS
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2D and 3D bone registration methods
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Deep learning bone and artery ultrasound segmentation
Number of subjects: 30
Study: 39633218

Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (PCC) 15 IU/kg
Number of subjects: 99

Group type: COMPARATOR
Intervention: Plasma 10-15 ml/kg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: PCC
Number of subjects: 99

Group type: COMPARATOR
Intervention: Plasma
Number of subjects: 99
Study: 39633261

Group type: EXPERIMENTAL
Intervention: Home-based multicomponent program (strength and balance training, bladder training with urge suppression strategies, home hazard assessment)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Educational booklet on falls prevention and behavioral treatment for urinary incontinence (control group)
Number of subjects: 314
Study: 39633319

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Therapist adherence (assessed by patients, therapists, and observers)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Therapist competence (assessed using the Cognitive Therapy Scale-Revised)
Number of subjects: 85
Study: 39633321

Group type: EXPERIMENTAL
Intervention: High-fiber dietary intervention (HFDI) with a target fiber of 50 g/day from whole foods
Number of subjects: 45

Group type: COMPARATOR
Intervention: Healthy control diet with a target fiber of 20 g/day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High-fiber dietary intervention (HFDI)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Healthy control diet
Number of subjects: 45
Study: 39633367

Group type: EXPERIMENTAL
Intervention: Technology-enabled anticipatory guidance and peer support through four rounds of online parent empowerment sessions.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional oral health education materials (Control group).
Number of subjects: 0
Study: 39633405

Group type: EXPERIMENTAL
Intervention: manual-based videoconferencing cognitive behavioral therapy (vCBT)
Number of subjects: 20
Study: 39633425

Group type: EXPERIMENTAL
Intervention: Ureteral stent omission
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ureteral stent placement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both cohorts (stent omission and placement)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with patients and urologists
Number of subjects: 0
Study: 39633467

Group type: EXPERIMENTAL
Intervention: Midodrine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 39633570

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 2g administered within 45 minutes of symptom onset
Number of subjects: 3400

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 3400
Study: 39633573

Group type: EXPERIMENTAL
Intervention: Therapeutic dose Heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39634173

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus capecitabine (GX)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Gemcitabine plus carboplatin (GC)
Number of subjects: 187
Study: 39634198

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (PORT)
Number of subjects: 132
Study: 39634261

Group type: EXPERIMENTAL
Intervention: Ponatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Asciminib
Number of subjects: 0
Study: 39634773

Group type: EXPERIMENTAL
Intervention: Low frequency continuous waveform group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intermittent waveform group
Number of subjects: 120